Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

Age and factors associated with access and time to post-operative adjuvant chemotherapy in colon cancer: a French epidemiological study.

Capsec J, Lefebvre C, Chupé F, Heitzmann P, Raveneau C, Dardaine-Giraud V, Sauger C, Lagasse JP, Kraft K, Linassier C, Dorval E.

J Gastrointest Oncol. 2017 Oct;8(5):842-849. doi: 10.21037/jgo.2017.06.13.

2.

Comparison of adjuvant FOLFOX4 chemotherapy and oral UFUR/LV following adjuvant FOLFOX4 chemotherapy in patients with stage III colon cancer subsequent to radical resection.

Huang MY, Huang CM, Tsai HL, Huang CW, Hsieh HM, Yeh YS, Wu JY, Wang WM, Wang JY.

Oncol Lett. 2017 Dec;14(6):6754-6762. doi: 10.3892/ol.2017.7073. Epub 2017 Sep 26.

3.

Clinical-Pathological Correlation of KRAS Mutation Status in Metastatic Colorectal Adenocarcinoma.

Ribeiro KB, Ribeiro KB, Feres O, da Rocha JJR, Rapatoni L, Garcia SB, Silva AR, da Silva Castro Perdona G, de Souza HCC, Santillan SIG, de Oliveira HF, da Cunha Tirapelli DP, Peria FM.

World J Oncol. 2013 Oct;4(4-5):179-187. doi: 10.4021/wjon719w. Epub 2013 Sep 27.

4.

Recurrence-associated gene signature optimizes recurrence-free survival prediction of colorectal cancer.

Tian X, Zhu X, Yan T, Yu C, Shen C, Hu Y, Hong J, Chen H, Fang JY.

Mol Oncol. 2017 Nov;11(11):1544-1560. doi: 10.1002/1878-0261.12117. Epub 2017 Sep 23.

5.

Health care disparities among octogenarians and nonagenarians with stage II and III rectal cancer.

Cassidy RJ, Switchenko JM, Cheng E, Jiang R, Jhaveri J, Patel KR, Tanenbaum DG, Russell MC, Steuer CE, Gillespie TW, McDonald MW, Landry JC.

Cancer. 2017 Nov 15;123(22):4325-4336. doi: 10.1002/cncr.30896. Epub 2017 Jul 31.

PMID:
28759121
6.

Population-based study of effectiveness of neoadjuvant radiotherapy on survival in US rectal cancer patients according to age.

Wu L, Pang S, Yao Q, Jian C, Lin P, Feng F, Li H, Li Y.

Sci Rep. 2017 Jun 14;7(1):3471. doi: 10.1038/s41598-017-02992-7.

7.

Prognostic Value of E-cadherin-, CD44-, and MSH2-associated Nomograms in Patients With Stage II and III Colorectal Cancer.

Qu J, Jiang Y, Liu H, Deng H, Yu J, Qi X, Ge W, Li G.

Transl Oncol. 2017 Apr;10(2):121-131. doi: 10.1016/j.tranon.2016.12.005. Epub 2017 Jan 23.

8.

Adjuvant systemic chemotherapy for stages II and III colon cancer after complete resection: a clinical practice guideline.

Meyers BM, Cosby R, Quereshy F, Jonker D.

Curr Oncol. 2016 Dec;23(6):418-424. doi: 10.3747/co.23.3330. Epub 2016 Dec 21.

9.

High expression of miR-181c as a predictive marker of recurrence in stage II colorectal cancer.

Yamazaki N, Koga Y, Taniguchi H, Kojima M, Kanemitsu Y, Saito N, Matsumura Y.

Oncotarget. 2017 Jan 24;8(4):6970-6983. doi: 10.18632/oncotarget.14344.

10.

The C-Reactive Protein to Albumin Ratio as a Predictor of Severe Side Effects of Adjuvant Chemotherapy in Stage III Colorectal Cancer Patients.

Tominaga T, Nonaka T, Sumida Y, Hidaka S, Sawai T, Nagayasu T.

PLoS One. 2016 Dec 8;11(12):e0167967. doi: 10.1371/journal.pone.0167967. eCollection 2016.

11.

Tumors with unmethylated MLH1 and the CpG island methylator phenotype are associated with a poor prognosis in stage II colorectal cancer patients.

Fu T, Liu Y, Li K, Wan W, Pappou EP, Iacobuzio-Donahue CA, Kerner Z, Baylin SB, Wolfgang CL, Ahuja N.

Oncotarget. 2016 Dec 27;7(52):86480-86489. doi: 10.18632/oncotarget.13441.

12.
13.

Can we eliminate neoadjuvant chemoradiotherapy in favor of neoadjuvant multiagent chemotherapy for select stage II/III rectal adenocarcinomas: Analysis of the National Cancer Data base.

Cassidy RJ, Liu Y, Patel K, Zhong J, Steuer CE, Kooby DA, Russell MC, Gillespie TW, Landry JC.

Cancer. 2017 Mar 1;123(5):783-793. doi: 10.1002/cncr.30410. Epub 2016 Oct 25.

PMID:
27780316
14.

Effectiveness of adjuvant chemotherapy for elderly patients with lymph node-positive colorectal cancer.

Tominaga T, Nonaka T, Sumida Y, Hidaka S, Sawai T, Nagayasu T.

World J Surg Oncol. 2016 Jul 28;14(1):197. doi: 10.1186/s12957-016-0959-5.

15.

Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer.

Casadaban L, Rauscher G, Aklilu M, Villenes D, Freels S, Maker AV.

Cancer. 2016 Nov 15;122(21):3277-3287. doi: 10.1002/cncr.30181. Epub 2016 Jul 15.

16.

Neoadjuvant treatment of rectal cancer: where are we now?

Kalyan A, Rozelle S, Benson A 3rd.

Gastroenterol Rep (Oxf). 2016 Aug;4(3):206-9. doi: 10.1093/gastro/gow017. Epub 2016 Jul 12. No abstract available.

17.

Systematic Review: Adjuvant Chemotherapy for Locally Advanced Rectal Cancer with respect to Stage of Disease.

Hajibandeh S, Hajibandeh S.

Int Sch Res Notices. 2015 Feb 8;2015:710569. doi: 10.1155/2015/710569. eCollection 2015. Review.

18.

Possible contribution of IMRT in postoperative radiochemotherapy for rectal cancer: analysis on 1798 patients by prediction model.

Liu WY, Dinapoli N, Wang X, Meldolesi E, Gambacorta MA, Chiloiro G, Ren H, Fang H, Lu NN, Tang Y, Deng L, Wang JY, Jing H, Xiao Q, Feng YR, Li YX, Wang SL, Song YW, Liu YP, Wang WH, Valentini V, Jin J.

Oncotarget. 2016 Jul 19;7(29):46536-46544. doi: 10.18632/oncotarget.10228.

19.

Quantitative proteomics reveals that distant recurrence-associated protein R-Ras and Transgelin predict post-surgical survival in patients with Stage III colorectal cancer.

Xu L, Gao Y, Chen Y, Xiao Y, He Q, Qiu H, Ge W.

Oncotarget. 2016 Jul 12;7(28):43868-43893. doi: 10.18632/oncotarget.9701.

20.

Detection of Biomarkers with Solid-Phase Proximity Ligation Assay in Patients with Colorectal Cancer.

Ghanipour L, Darmanis S, Landegren U, Glimelius B, Påhlman L, Birgisson H.

Transl Oncol. 2016 Jun;9(3):251-5. doi: 10.1016/j.tranon.2016.04.001.

Supplemental Content

Support Center